Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance
Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consider President Donald Trump's new advice that pregnant women avoid the pain killer as it decides whether to revive their lawsuits.
RFK Jr.'s team wanted to tout an autism therapy. But a meeting with Tylenol's maker convinced the U.S. health secretary to put the emphasis on acetaminophen
The heads of key health agencies advocated for putting the emphasis on leucovorin, but Kennedy became convinced that he had a moral duty to get the word out about the risk of acetaminophen.
Kenvue: This Too Shall Pass
Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity. The market reaction appears to be an overreaction, as Tylenol accounts for roughly $1 billion in sales and a fraction of Kenvue's total revenue. The current valuation implies an unrealistic 40%+ decline in Tylenol sales, which seems excessive given the actual business impact.
Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
Pharmaceutical Stock Bounces Off Record Lows
Kenvue Inc (NYSE:KVUE) stock is up 3.9% to trade at $17.62 at last check, erasing some of yesterday's losses that followed the Trump administration connection between the use of acetaminophen -- the active ingredient of the company's Tylenol pain drug -- in pregnancy and autism.
Tylenol: Kenvue's Sobering Reality
I'm initiating Kenvue Inc. with a Buy after a sharp selloff following President Donald Trump's remarks on Monday linking Tylenol with autism. KVUE's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Despite Self Care sales weakness and ongoing litigation concerns, Tylenol continues to gain market share and new product launches are underway.
Tylenol Maker Kenvue Shares Rebound After Trump Links Drug To Autism
23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Association.
Wall Street Breakfast Podcast: Kenvue In Focus
Kenvue (KVUE) rebounds 6% premarket after sharp drop, following FDA warning on acetaminophen use during pregnancy and company defense of Tylenol's safety. Boeing (BA) secures Uzbekistan Airways' largest-ever order for up to 22 Dreamliners, supporting fleet modernization and international route expansion.
Kenvue stock rallies off record low after Trump press conference on alleged Tylenol-autism link
Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn't offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.
Tylenol-maker Kenvue shares bounce, Trump claims face pushback
Tylenol-maker Kenvue stock rose in European trading on Tuesday, even after U.S. President Donald Trump linked its popular pain medication to autism risk during pregnancy.
Kenvue takes a $1.4bn Tylenol hit
Kenvue Inc (NYSE:KVUE) shares dropped 4% at the open on Monday, erasing about $1.4 billion in market value, after a report that Trump administration officials plan to warn pregnant women against taking Tylenol unless they have a fever. The Washington Post said the guidance will claim the active ingredient, acetaminophen, is linked to autism, citing unnamed sources.
